DNA/MVA vaccines for HIV/AIDS

Vaccines

Volumn 2, Issue 1, 2014, Pages 160-178

  Iyer, Smita S ^a   Amara, Rama R ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Adjuvant; CD40L; GM CSF; Rhesus macaque; SIV

Indexed keywords

DNA VACCINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HUMAN GROWTH HORMONE; INTERLEUKIN 2; INTERLEUKIN 4; MODIFIED VACCINIA VIRUS ANKARA VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ELECTROPORATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SURVIVAL; VACCINATION;

EID: 85019427452     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2010160     Document Type: Review

References (78)

1. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.;et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209-2220.
2. Hammer, S.M.; Sobieszczyk, M.E.; Janes, H.; Karuna, S.T.; Mulligan, M.J.; Grove, D.; Koblin, B.A.; Buchbinder, S.P.; Keefer, M.C.; Tomaras, G.D.;et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 2013, 369, 2083-2092.
3. Michael, N.L. Rare serotype adenoviral vectors for HIV vaccine development. J. Clin. Invest 2012, 122, 25-27.
4. IAVI Report. Clinical Trials Database. November 2013; Available from: http://www.iavireport. org/Trials-Database/Pages/default.aspx(accessed on 31 January 2014)
5. Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247, 1465-1468.
6. Tang, D.C.; deVit, M.; Johnston, S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356, 152-154.
7. Ulmer, J.B.; Donnelly, J.J.; Parker, S.E.; Rhodes, G.H.; Felgner, P.L.; Dwarki, V.J.; Gromkowski, S.H.; Deck, R.R.; DeWitt, C.M.; Feredman, A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745-1749.
8. Robinson, H.L.; Hunt, L.A.; Webster, R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993, 11, 957-960.
9. Fynan, E.F.; Webster, R.G.; Fuller, D.H.; Haynes, J.R.; Santoro, J.C.; Robinson, H.L. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 1993, 90, 11478-11482.
10. Wang, B.; Ugen, K.E.; Srikantan, V.; Agadjanyan, M.G.; Dang, K.; Refaeli, Y.; Sato, A.I.; Boyer, J.; Williams, W.V.; Weiner, D.B. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1993, 90, 4156-4160.
11. Peet, N.M.; McKeating, J.A.; Ramos, B.; Klonisch, T.; de Souza, J.B.; Delves, P.J.; Lund, T. Comparison of nucleic acid and protein immunization for induction of antibodies specific for HIV-1 gp120. Clin. Exp. Immunol. 1997, 109, 226-232.
12. Jiao, S.S.; Williams, P.; Berg, R.K.; Hodgeman, B.A.; Liu, L.J.; Repetto, G.; Wolff, J.A. Direct gene transfer into nonhuman primate myofibers in vivo. Hum. Gene Ther. 1992, 3, 21-33.
13. Wang, B.; Boyer, J.; Srikantan, V.; Uqen, K.; Gilbert, L.; Phan, C.; Dang, K.; Merva, M.; Aqadjanyan, M.G. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology 1995, 211, 102-112.
14. Boyer, J.D.; Uqen, K.E.; Wang, B.; Aqadjanyan, M.; Gilbert, L.; Baqarazzi, M.L.; Chatterqoon, M.; Frost, P.; Javadian, A.; Williams, W.V.;et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 1997, 3, 526-532
15. Donnelly, J.J.; Ulmer, J.B.; Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 1997, 15, 617-648.
16. Letvin, N.L.; Montefiori, D.C.; Yasutomi, Y.; Perry, H.C.; Davies, M.E.; Lekutis, C.; Alroy, M.; Freed, D.C.; Lord, C.I.; Handt, L.K.; et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA 1997, 94, 9378-9383.
17. Fuller, D.H.; Simpson, L.; Cole, K.S.; Clements, J.E.; Panicali, D.L.; Montelaro, R.C.; Murphey-Corb, M.; Haynes, J.R. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol. Cell Biol. 1997, 75, 389-396.
18. Schneider, J.; Gilbert, S.C.; Blanchard, T.J.; Hanke, T.; Robson, K.J.; Hannan, C.M.; Becker, M.; Sinden, R.; Smith, G.L.; Hill, A.V. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 1998, 4, 397-402.
19. Robinson, H.L.; Montefiori, D.C.; Johnson, P.; Manson, K.H.; Kalish, M.; Lifson, J.D.; Rizvi, T.A.; Lu, S.; Hu, S.L.; Mazzara, G.P.; et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 1999, 5, 526-534.
20. Allen, T.M.; Voqel, T.U.; Fuller, D.H.; Mothé, B.R.; Steffen, S.; Boyson, J.E.; Shipley, T.; Fuller, J.; Hanke, T.; Sette, A. et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 2000, 164, 4968-4978.
21. Hanke, T.; McMichael, A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol. Lett. 1999, 66, 177-181.
22. Amara, R.R.; Villinger, F.; Altman, J.D.; Lydy, S.L.; O'Neil, S.P.; Staprans, S.I.; Montefiori, D.C.; Xu, Y.; Herndon, J.G.; Wyatt, L.S. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292, 69-74.
23. Mwau, M.; Cebere, I.; Sutton, J.; Chikoti, P.; Winstone, N.; Wee, E.G.; Beattie, T.; Chen, Y.H.; Dorrell, L.; McShane, H. et al. A human immunodeficiency virus 1(HIV-1) clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara(MVA) vaccines in humans. J. Gen. Virol. 2004, 85, 911-919.
24. Mulligan, M.J.; Russell, N.D.; Celum, C.; Kahn, J.; Noonan, E.; Montefiori, D.C.; Ferrari, G.; Weinhold, K.J.; Smith, J.M.; Amara, R.R. et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retrovir. 2006, 22, 678-683.
25. Ondondo, B.O.; Yang, H.; Dong, T.; di Gleria, K.; Suttill, A.; Conlon, C.; Brown, D.; Williams, P.; Rowland-Jones, S.L.; Hanke, T. et al. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur. J. Immunol. 2006, 36, 2585-2594.
26. Goonetilleke, N.; Moore, S.; Dally, L.; Winstone, N.; Cebere, I.; Mahmoud, A.; Pinheiro, S.; Gillespie, G.; Brown, D.; Loach, V. et al. Induction of multifunctional human immunodeficiency virus type 1(HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 2006, 80, 4717-4728.
27. Sandstrom, E.; Nilsson, C.; Hejdeman, B.; Brave, A.; Bratt, G.; Robb, M.; Cox, J.; Vancott, T.; Marovich, M.; Stout, R. et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect Dis. 2008, 198, 1482-1490.
28. Cebere, I.; Dorrell, L.; McShane, H.; Simmons, A.; McCormack, S.; Schmidt, C.; Smith, C.; Brooks, M.; Roberts, J.E.; Darwin, S.C. et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1(HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006, 24, 417-425.
29. Hanke, T.; Goonetilleke, N.; McMichael, A.J.; Dorrell, L. Clinical experience with plasmid DNA-and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 2007, 88, 1-12.
30. Guimaraes-Walker, A.; Mackie, N.; McCormack, S.; Hanke, T.; Schmidt, C.; Gilmour, J.; Barin, B.; McMichael, A.; Weber, J.; Legg, K. et al. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008, 26, 6671-6677.
31. Aboud, S.; Nilsson, C.; Karlen, K.; Marovich, M.; Wahren, B.; Sandstrom, E.; Gaines, H.; Biberfeld, G.; Godoy-Ramirez, K. Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clin. Vaccine Immunol. 2010, 17, 1124-1131.
32. Goepfert, P.A.; Elizaga, M.L.; Sato, A.; Qin, L.; Cardinali, M.; Hay, C.M.; Hural, J.; DeRosa, S.C.; DeFawe, O.D.; Tomaras, G.D. et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J. Infect Dis. 2011, 203, 610-619.
33. Nilsson, C.; Godoy-Ramirez, K.; Hejdeman, B.; Brave, A.; Gudmundsdotter, L.; Hallengard, D.; Currier, J.R.; Wieczorek, L.; Hasselrot, K.; Earl, P.L. et al. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus Ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-Boosted Swedish vaccinees. AIDS Res. Hum. Retrovir. 2013, doi:10.1089/aid.2013.0149.
34. Kutzler, M.A.; Weiner, D.B. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 2008, 9, 776-788.
35. Donnelly, J.J.; Liu, M.A.; Ulmer, J.B.and DNA vaccines. Am. J. Respir. Crit. Care Med. 2000, 162, S190-S193.
36. Corr, M.; Lee, D.J.; Carson, D.A.; Tighe, H. Gene vaccination with naked plasmid DNA: Mechanism of CTL priming. J. Exp. Med. 1996, 184, 1555-1560.
37. Asakura, Y.; Liu, L.J.; Shono, N.; Hinkula, J.; Kjerrstrom, A.; Aoki, I.; Okuda, K.; Wahren, B.; Fukushima, J. Th1-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production. Clin. Exp. Immunol. 2000, 119, 130-139.
38. Feltquate, D.M.; Heaney, S.; Webster, R.G.; Robinson, H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 1997, 158, 2278-2784.
39. Pillai, V.B.; Hellerstein, M.; Yu, T.; Amara, R.R.; Robinson, H.L. Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines. Vaccine 2008, 26, 1136-1141.
40. Flingai, S.; Czerwonko, M.; Goodman, J.; Kudchodkar, S.B.; Muthumani, K.; Weiner, D.B. Synthetic DNA vaccines: Improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol. 2013, 4, 354.
41. MacGregor, R.R.; Ginsberg, R.; Ugen, K.E.; Baine, Y.; Kang, C.U.; Tu, X.M.; Higgins, T.; Weiner, D.B.; Boyer, J.D. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS 2002, 16, 2137-2143.
42. Sardesai, N.Y.; Weiner, D.B. Electroporation delivery of DNA vaccines: Prospects for success. Curr. Opin. Immunol. 2011, 23, 421-429.
43. Luckay, A.; Sidhu, M.K.; Kjeken, R.; Megati, S.; Chong, S.Y.; Roopchand, V.; Garcia-Hand, D.; Abdullah, R.; Braun, R.; Montefiori, D.C.; et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 2007, 81, 5257-5269.
44. Sutter, G.; Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 1992, 89, 10847-10851.
45. Carroll, M.W.; Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238, 198-211.
46. Earl, P.L.; Americo, J.L.; Wyatt, L.S.; Eller, L.A.; Whitbeck, J.C.; Cohen, G.H.; Eisenberg, R.J.; Hartmann, C.J.; Jackson, D.L.; Kulesh, D.A. et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428, 182-185.
47. Seth, A.; Ourmanov, I.; Kuroda, M.J.; Schmitz, J.E.; Carroll, M.W.; Wyatt, L.S.; Moss, B.; Forman, M.A.; Hirsch, V.M.; Letvin, N.L. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc. Natl. Acad. Sci. USA 1998, 95, 10112-10116.
48. Sadagopal, S.; Amara, R.R.; Montefiori, D.C.; Wyatt, L.S.; Staprans, S.I.; Kozyr, N.L.; McClure, H.M.; Moss, B.; Robinson, H.L. Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: Stable low-breadth and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. J. Virol. 2005, 79, 3243-3253.
49. Amara, R.R.; Smith, J.M.; Staprans, S.I.; Montefiori, D.C.; Villinger, F.; Altman, J.D.; O'Neil, S.P.; Kozyr, N.L.; Xu, Y.; Wyatt, L.S. et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 2002, 76, 6138-6146.
50. Sadagopal, S.; Amara, R.R.; Kannanganat, S.; Sharma, S.; Chennareddi, L.; Robinson, H.L. Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J. Virol. 2008, 82,4149-4153.
51. Amara, R.R.; Ibegbu, C.; Villinger, F.; Montefiori, D.C.; Sharma, S.; Nigam, P.; Xu, Y.; McClure, H.M.; Robinson, H.L. Studies using a viral challenge and CD8 T cell depletions on the roles of cellular and humoral immunity in the control of an SHIV-89.6P challenge in DNA/MVA- vaccinated macaques. Virology 2005, 343, 246-255.
52. Amara, R.R.; Villinger, F.; Staprans, S.I.; Altman, J.D.; Montefiori, D.C.; Kozyr, N.L.; Xu, Y.; Wyatt, L.S.; Earl, P.L.; Herndon, J.G.; et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara(MVA) and DNA/MVA vaccines. J. Virol. 2002, 76, 7625-7631.
53. Lai, L.; Kwa, S.F.; Kozlowski, P.A.; Montefiori, D.C.; Nolen, T.L.; Hudgens, M.G.; Johnson, W.E.; Ferrari, G.; Hirsch, V.M.; Felber, B.K. et al. SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses. Vaccine 2012, 30, 1737-1745.
54. Geissler, M.; Gesien, A.; Tokushige, K.; Wands, J.R. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J. Immunol. 1997, 158, 1231-1237.
55. Barouch, D.H.; Santra, S.; Schmitz, J.E.; Kuroda, M.J.; Fu, T.M.; Wagner, W.; Bilska, M.; Craiu, A.; Zheng, X.X.; Krivulka, G.R. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290, 486-492.
56. Baden, L.R.; Blattner, W.A.; Morgan, C.; Huang, Y.; Defawe, O.D.; Sobieszczyk, M.E.; Kochar, N.; Tomaras, G.D.; McElrath, M.J.; Russell, N. et al. Timing of plasmid cytokine(IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J. Infect Dis. 2011, 204, 1541-1549.
57. Morrissey, P.J.; Bressler, L.; Park, L.S.; Alpert, A.; Gillis, S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigenpresenting cells. J. Immunol. 1987, 139, 1113-1119.
58. Elliott, M.J.; Strasser, A.; Metcalf, D. Selective up-regulation of macrophage function in granulocyte-macrophage colony-stimulating factor transgenic mice. J. Immunol. 1991, 147, 2957-2963.
59. Haddad, D.; Ramprakash, J.; Sedegah, M.; Charoenvit, Y.; Baumgartner, R.; Kumar, S.; Hoffman, S.L.; Weiss, W.R. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J. Immunol. 2000, 165, 3772-3781.
60. Robinson, H.L.; Montefiori, D.C.; Villinger, F.; Robinson, J.E.; Sharma, S.; Wyatt, L.S.; Earl, P.L.; McClure, H.M.; Moss, B.; Amara, R.R. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 2006, 352, 285-294.
61. Lai, L.; Vodros, D.; Kozlowski, P.A.; Montefiori, D.C.; Wilson, R.L.; Akerstrom, V.L.; Chennareddi, L.; Yu, T.; Kannanganat, S.; Ofielu, L. et al. GM-CSF DNA: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007, 369, 153-167.
62. Lai, L.; Kwa, S.; Kozlowski, P.A.; Montefiori, D.C.; Ferrari, G.; Johnson, W.E.; Hirsch, V.; Villinger, F.; Chennareddi, L.; Earl, P.L. et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J. Infect Dis. 2011, 204, 164-173.
63. Hellerstein, M.; Xu, Y.; Marino, T.; Lu, S.; Yi, H.; Wright, E.R.; Robinson, H.L. Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine. Hum. Vaccin. Immunother. 2012, 8, 1654-1658.
64. Van Kooten, C.; Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67, 2-17.
65. Van Mierlo, G.J.; den Boer, A.T.; Medema, J.P.; van der Voort, E.I.; Fransen, M.F.; Offringa, R.; Melief, C.J.; Toes, R.E. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 2002, 99, 5561-5566.
66. French, R.R.; Chan, H.T.; Tutt, A.L.; Glennie, M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 1999, 5, 548-553.
67. Quezada, S.A.; Jarvinen, L.Z.; Lind, E.F.; Noelle, R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 2004, 22, 307-328.
68. Kishi, Y.; Aiba, Y.; Higuchi, T.; Furukawa, K.; Tokuhisa, T.; Takemori, T.; Tsubata, T. Augmented antibody response with premature germinal center regression in CD40L transgenic mice. J. Immunol. 2010, 185, 211-219.
69. Crotty, S. Follicular helper CD4 T cells(TFH). Annu. Rev. Immunol. 2011, 29, 621-663.
70. Vonderheide, R.H.; Dutcher, J.P.; Anderson, J.E.; Eckhardt, S.G.; Stephans, K.F.; Razvillas, B.; Garl, S.; Butine, M.D.; Perry, V.P.; Armitage, R.J. et al. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 2001, 19, 3280-3287.
71. Stone, G.W.; Barzee, S.; Snarsky, V.; Kee, K.; Spina, C.A.; Yu, X.F.; Kornbluth, R.S. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J. Virol. 2006, 80, 1762-1772.
72. Gomez, C.E.; Najera, J.L.; Sanchez, R.; Jimenez, V.; Esteban, M. Multimeric soluble CD40 ligand(sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 2009, 27, 3165-3174.
73. Liu, J.; Yu, Q.; Stone, G.W.; Yue, F.Y.; Ngai, N.; Jones, R.B.; Kornbluth, R.S.; Ostrowski, M.A. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals. Vaccine 2008, 26, 4062-4072.
74. Wyzgol, A.; Yu, Q.; Stone, G.W.; Yue, F.Y.; Ngai, N.; Jones, R.B.; Kornbluth, R.S.; Ostrowski, M.A. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J. Immunol. 2009, 183, 1851-1861.
75. Calarota, S.A.; Leandersson, A.C.; Bratt, G.; Hinkula, J.; Klinman, D.M.; Weinhold, K.J.; Sandstrom, E.; Wahren, B. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J. Immunol. 1999, 163, 2330-2338.
76. Harari, A.; Bart, P.A.; Stohr, W.; Tapia, G.; Garcia, M.; Medjitna-Rais, E.; Burnet, S.; Cellerai, C.; Erlwein, O.; Barber, T. et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 2008, 205, 63-77.
77. Mehendale, S.; Thakar, M.; Sahay, S.; Kumar, M.; Shete, A.; Sathyamurthi, P.; Verma, A.; Kurle, S.; Shrotri, A.; Gilmour, J. et al. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers. PLoS One 2013, 8, e55831.
78. Hayes, P.; Gilmour, J.; von Lieven, A.; Gill, D.; Clark, L.; Kopycinski, J.; Cheeseman, H.; Chung, A.; Alter, G.; Dally, L. et al. Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults. Clin. Vaccine Immunol. 2013, 20, 397-408.